References
- O'Connor P. G., Selwyn P. A., Schottenfeld R. S. Medical care for injection‐drug users with human immunodeficiency virus infection. N. Engl. J. Med 1994; 331: 450–459
- Department of Health and Human Services, Rockville, Maryland 1991, Policy Report of the Physician Consortium on Substance Abuse Education
- Jaffe J. H. Drug addiction and drug abuse. Goodman and Gilman's: The Pharmacological Basis of Therapeutics8th ed., A. G. Gilman, T. W. Rall, A. S. Nies, P. Taylor. Pergamon Press, New York 1990; 522–573
- Ball J. C., Ross A. The Effectiveness of Methadone Maintenance Treatment. Springer‐Verlag, New York 1991
- O'Connor P. G., Waugh M. E., Carroll K. M., et al. Primary care‐based ambulatory opioid detoxification: The results of a clinical trial. J. Gen. Intern. Med 1995; 10(5)255–260
- Novick D. M., Pascarelli E. F., Joseph H., et al. Methadone maintenance patients in general medical practice: A preliminary report. JAMA 1988; 259(22)3299–3302
- Mello N. K., Mendelson J. H. Buprenorphine suppresses heroin use by heroin addicts. Science 1980; 207: 657–659
- Johnson R. E., Fudala P. G. Development of buprenorphine for the treatment of opioid dependence. Buprenorphine: An Alternative Treatment for Opioid Dependence, J. Blaine. NIDA Research Monograph Series 121, National Institute on Drug Abuse, Rockville, Maryland 1992; 120–141
- Amass L., Bickel W. K., Higgins S. T., et al. Alternate‐day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 54: 1215–1228
- Bickel W. K., Stitzer M. L., Bigelow G. E., et al. Buprenorphine: Dose related blockage of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther 1988; 247: 47–53
- O'Connor P. G., Molde S., Henry S., et al. Human immunodeficiency virus infection in intravenous drug users: A model for primary care. Am. J. Med 1992; 93: 382–386
- American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders3rd ed. American Psychiatric Association, Washington, D.C. 1987
- Hughes J. R., Guest S. W., Keenan R. M., et al. Nicotine vs. placebo gum in general medicine practice. JAMA 1989; 261: 1300–1305
- Fiore M. C., Jorenby D. E., Baker T. B., et al. Tobacco dependence and the nicotine patch: Clinical guidelines for effective use. JAMA 1992; 268: 2687–2694
- McLellan A. T., Arndt I. O., Metzger D. S., et al. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269: 1953–1959
- Rounsaville B. J., Weismann M. M., Crits‐Cristoph K., et al. Diagnosis and symptoms of depression in opiate addicts: Course and relationship to treatment outcome. Arch. Gen. Psychiatry 1982; 39: 151–156
- Walsh S. L., Preston L. K., Stitzer M. L., Cone E. J., Bigelow G. E. Clinical pharmacology of buprenorphine: Ceiling effects at higher doses. Clin. Pharmacol. Ther 1994; 55: 569–580